Welcome to the new Rare Kidney Disease Show part of the RKD Scientific Network sponsored by Travere Therapeutics. The Rare Kidney Disease Show is your primary source for cutting-edge insights, expert perspectives, and pivotal updates in nephrology. Led by our panel of experts, explore the advances in glomerular nephropathies through compelling conversations, challenging case studies, and discussions tackling hot topics. Join us as we strive to provide you with the ultimate resource to support your clinical practice and advance patient care.
Rare Kidney Disease Show
Claim This Podcastby Travere Therapeutics
5.0(2 reviews)
9 episodes
Updated Bi-weekly
Accepts GuestsHas Sponsors
13
Podcast Authority
BetaPoorBased on show quality, social media presence, reviews, charts, and more
Quality2
Social0
YouTube0
Engagement60
Podcast Overview
Welcome to the new Rare Kidney Disease Show part of the RKD Scientific Network sponsored by Travere Therapeutics. The Rare Kidney Disease Show is your primary source for cutting-edge insights, expert perspectives, and pivotal updates in nephrology. Led by our panel of experts, explore the advances in glomerular nephropathies through compelling conversations, challenging case studies, and discussions tackling hot topics. Join us as we strive to provide you with the ultimate resource to support your clinical practice and advance patient care.
Language
🇺🇲
Publishing Since
3/20/2024
Unlock The Full Podcast Authority Score Report
See how your podcast performs across key metrics
13
Podcast Authority
BetaPoorBased on show quality, social media presence, reviews, charts, and more
Quality2
Social0
YouTube0
Engagement60
4
Excellent Areas
1
Good Performance
14
Growth Opportunities
excellent
Episode Length
21 minutes
Performing excellently!
good
iTunes Tags
7.6/10
Recommendations available
Unlock the full report to see detailed tips
poor
Publishing Consistency
Every 66 days
Recommendations available
Unlock the full report to see detailed tips
+16 More Metrics
Unlock comprehensive insights including:
- • YouTube presence analysis
- • Social media reach metrics
- • RSS compliance scoring
- • Podcast 2.0 features
- • Technical standards
What's Included in Your Full Report
Detailed Analytics
- Complete breakdown of all 19 authority metrics
- Personalized recommendations for each metric
- Industry benchmarks and comparisons
- Technical RSS feed analysis and compliance scoring
Growth Strategies
- Step-by-step action plans for improvement
- Quick wins to boost your score immediately
- Pro tips from successful podcasters
Get your free podcast insights report
See how your show performs across every key metric
Instant delivery
No spam
Attract Better Guests
High authority scores make your podcast more attractive to industry leaders and influencers who want to appear on credible shows.
Secure Sponsorships
Sponsors look for podcasts with proven authority and engagement. Your score demonstrates your podcast's value to potential partners.
Grow Your Audience
Understanding your strengths and weaknesses helps you make data-driven decisions to expand your listener base effectively.
1 verified contact email on file for Rare Kidney Disease Show
Pitch yourself as a guest, propose sponsorships, or reach out directly to the host.
Recent Episodes
April 10, 2026
Rewriting Kidney Care with Endothelin and Proteinuria
<p><br>Welcome to Travere Therapeutics’s Rare Kidney Disease podcast, where rare kidney disease gets a spotlight. Host Chris Gisler brings together two leading voices in nephrology, Dr. Donald Kohan and Dr. Yelena Drexler, for an energetic conversation about why proteinuria matters so much in diseases like FSGS and IgA nephropathy.</p><p>What starts as a discussion of proteinuria as a lab value soon deepens: what is it, why does it mean more than just numbers, and how does it actually drive kidney injury? </p><p>Dr. Donald Kohan breaks down the biology of endothelin, showing its role at every stage of glomerulonephritis. At the same time, Dr. Yelena Drexler links research to real patient care and shares the practical impact of proteinuria on outcomes.</p><p>Whether you’re a clinician, researcher, or patient advocate, this episode delivers clear takeaways—from the latest studies shaping proteinuria targets to the call for multi-pathway, biology-informed treatment strategies.</p><p><br><strong>Speakers:</strong></p><ul><li>Dr. Chris Gisler is a medical director at Travere Therapeutics and an adult Nephrologist</li><li>Dr. Donald Kohan is a Professor of Medicine, Division of Nephrology & Hypertension at the University of Utah</li><li>Dr. Yelena Drexler is an Associate Professor of Clinical Medicine, Division of Nephrology & Hypertension at the University of Miami </li></ul><p><strong>Disclaimer:</strong> </p><p>Guest speakers of the Rare Kidney Disease Show may be paid consultants of Travere Therapeutics. This podcast episode was recorded on March 6, 2026. Please always consult updated sources for the latest information, as information discussed may have changed since the recording date.</p>
September 2, 2025
Insights from the SPARTAN Study with Drs. Jonathan Barratt and Shikha Wadhwani
<p>In this episode, Drs. Jonathan Barratt and Shikha Wadhwani discuss findings from the SPARTAN study, a Phase 2 open-label, single-arm trial evaluating sparsentan in 12 treatment-naïve patients with IgA nephropathy. The conversation explores the trial’s design, including assessments of proteinuria reduction and urinary biomarkers to better understand sparsentan’s mechanism of action.</p><p> </p><p>Results from SPARTAN demonstrate a 69% mean reduction in proteinuria at 24 weeks, alongside biomarker trends consistent with decreased glomerular inflammation. </p><p> </p><p>Dr. Barratt notes that no new safety signals emerged, with hypotension observed at a rate consistent with prior studies and no adverse hepatic events reported.</p><p> </p><p>Together, the experts reflect on how these data support the biological plausibility of sparsentan’s anti-inflammatory properties and may inform the development of biomarker-guided strategies in IgA nephropathy, including ongoing evaluation of sparsentan in the PROTECT trial.</p><p> </p><p><strong> Key Takeaways:</strong></p><ul><li><strong>SPARTAN demonstrated a robust mean reduction in proteinuria (~69%)</strong> in treatment-naïve patients with IgA nephropathy after 24 weeks of sparsentan therapy.</li><li><strong>Biomarker analysis</strong> revealed reductions in markers of macrophage activation, complement activity, and inflammatory cytokines, supporting the hypothesis of a potential anti-inflammatory effect.</li><li><strong>No new safety signals were observed</strong>; hypotension rates were consistent with earlier trials, and no clinically significant changes in hepatic function were reported.</li><li><strong>These findings contribute to our mechanistic understanding of sparsentan</strong> and provide a framework for future investigation of biomarkers from samples from larger studies such as PROTECT.</li></ul><p> </p><p><strong>Speakers: </strong></p><ul><li><strong>Dr. Jonathan Barratt</strong>, PhD, FRCP. Professor of Renal Medicine at the University of Leicester, where he leads the IgA Nephropathy Research Programme. He is internationally recognized for his leadership in translational and clinical research in glomerular diseases, particularly IgA nephropathy. Dr. Barratt directs the UK’s Rare Disease Group for the UK National Registry of Rare Kidney Diseases (RaDaR).</li><li><strong>Dr. Shikha Wadhwani</strong>, MD, MS, FASN. Associate Professor of Medicine in the Division of Nephrology and Vice Chair of Clinical Research in the Department of Medicine at University of Texas Medical Branch. She is also the inaugural Associate Research Officer for clinical research, overseeing clinical trials across all 5 schools at UTMB. She is the founding member of the International Society of Glomerular Disease (ISGD) and is steering a global effort aimed at supporting the growth and success of physician-trialists. In her spare time, Dr. Wadhwani co-hosts a podcast called Kidney Compass: Navigating Clinical Trials. </li></ul><p><strong>Disclaimer:</strong> </p><p>Guest speakers of the Rare Kidney Disease Show may be paid consultants of Travere Therapeutics. This podcast episode was recorded on July 25, 2025. Please always consult updated sources for the latest information, as information discussed may have changed since the recording date.</p>
May 27, 2025
From Podocyte to Patient: The Pathophysiology of FSGS
Doctors Tobias Huber and Chris Gisler examine the pathophysiology of FSGS, focusing on how podocyte injury causes glomerular filtration barrier breakdown and proteinuria, while also exploring endothelin 1 and angiotensin II's roles in worsening podocyte dysfunction; this is an interview.
9 total episodes available
Deep-dive analytics for Rare Kidney Disease Show
Frequently asked questions
Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.
- What is Rare Kidney Disease Show?
- How often does this podcast release new episodes?
This podcast updates bi-weekly.
- Where can I listen to this podcast?
This podcast is available on 9 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
- Does this podcast accept guests?
No, this podcast does not typically feature guests.
Legal Disclaimer
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.